Erleada (Apalutamide) Patent Expiration, LOE Window & CMS Spending

Erleada (Apalutamide) by Johnson & Johnson: FDA Orange Book core substance LOE 2033-06-04 (last listed 2041-01-14), 1 AB generics, $1.44B 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorJohnson & Johnson
FDA Application & PathwayN210951 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2033-06-04
Last Listed Patent or Exclusivity Date2041-01-14
Orange Book Patents (*PED Extensions)14 patents (0 *PED)
Active AB-Rated Generic Competitors1
2024 CMS Total Public Spend$1.44B
2024 Medicare Part D Spend$1.39B
2024 Medicaid Spend$52.1M
Reported Wholesale Price Change (CA SB 17)1 WAC filings (max 16.2% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Johnson & Johnson across sibling Meru public-data platforms.